Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
DNA and Cell Biology|December 11, 2014
Progesterone receptor gene (PROGINS) polymorphism correlates with late onset of migraineRaffaele Palmirotta, Piero Barbanti, Cristiano Ialongo, et al.
Pharmacogenomics|January 22, 2014
Association between migraine and ACE gene (insertion/deletion) polymorphism: the BioBIM studyRaffaele Palmirotta, Piero Barbanti, Giorgia Ludovici, et al.
Headache|July 26, 2021
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 studyPiero Barbanti, Cinzia Aurilia, Sabina Cevoli, et al.
Headache|December 18, 2020
Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Headache|June 14, 2021
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) projectPiero Barbanti, Luisa Fofi, Licia Grazzi, et al.
Frontiers in Neurology|April 16, 2026
Rapid effectiveness of eptinezumab to treat ongoing migraine attacks: preliminary data from an Italian multicenter real-world experience (the BE-FREE study)Luisa Fofi, Claudia Altamura, Marilena Marcosano, et al.
The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Cephalalgia : an International Journal of Headache|April 23, 2025
Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study)Fabrizio Vernieri, Luigi Francesco Iannone, Flavia Lo Castro, et al.
European Journal of Neurology|November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life studyFabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Cephalalgia : an International Journal of Headache|June 26, 2026
SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)Claudia Altamura, Luigi Francesco Iannone, Flavia Lo Castro, et al.
Pageof 5